Altium Capital Management LP Intra Cellular Therapies, Inc. Transaction History

Altium Capital Management LP

$283 Million
Q3 2024

A detailed history of Altium Capital Management LP transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Altium Capital Management LP holds 154,000 shares of ITCI stock, worth $13.2 Million. This represents 3.97% of its overall portfolio holdings.

Number of Shares

154,000

Previous 193,000 20.21%

Holding current value

$13.2 Million

Previous $13.2 Million 14.81%

% of portfolio

3.97%

Previous 7.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$67.99 - $80.84 $2.65 Million - $3.15 Million	-39,000 Reduced 20.21%	154,000 $11.3 Million
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $5.18 Million - $6.39 Million	80,000 Added 70.8%	193,000 $13.2 Million
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $2.7 Million - $3.18 Million	42,000 Added 59.15%	113,000 $7.82 Million
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $1.99 Million - $3.17 Million	43,000 Added 153.57%	71,000 $5.09 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $1.46 Million - $1.79 Million	28,000 New	28,000 $1.46 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $1.07 Million - $1.5 Million	25,000 Added 33.33%	100,000 $4.65 Million
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $2.26 Million - $3.45 Million	52,500 Added 233.33%	75,000 $4.28 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $871,650 - $1.4 Million	22,500 New	22,500 $1.38 Million
Q2 2021 Aug 13, 2021	SELL	$29.3 - $44.5 $2.59 Million - $3.93 Million	-88,326 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$30.8 - $39.51 $2 Million - $2.57 Million	-65,022 Reduced 42.4%	88,326 $3 Million
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $3.58 Million - $4.94 Million	153,348 New	153,348 $4.88 Million

Others Institutions Holding ITCI

# of Institutions

377

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.09B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.

Account

Altium Capital Management LP Intra Cellular Therapies, Inc. Transaction History